TL;DR
This paper presents a systems-pharmacology approach to design a drug combination that effectively inhibits Epithelial-Mesenchymal Transition (EMT), a key process in cancer metastasis. By integrating various bioinformatics tools and network analyses, they identified a combination of drugs targeting histone deacetylases (HDACs) and specific kinases (SRC and IKBK) that showed significant efficacy in preventing cancer cell invasion in a 3D microenvironment, suggesting a promising avenue for clinical trials.
What Problem Does This Paper Address?
Epithelial-Mesenchymal Transition (EMT) is a critical process that allows cancer cells to detach from their primary tumor, invade surrounding tissues, and metastasize to distant sites. Inhibiting EMT is a major goal in cancer therapy, but it's challenging due to the complex and redundant nature of the signaling pathways involved. Existing targeted therapies often face resistance, highlighting the need for rational drug combinations that hit multiple key players in EMT. This paper aims to address this by developing a systematic, in-silico driven approach to identify such combinations.
Methods
The authors employed a multi-faceted systems-pharmacology approach:
- Bioinformatic Integration: They compiled EMT-associated gene signatures from multiple published studies to create a comprehensive "EMT seed gene library."
- Network Analysis: They used tools like Cytoscape, BINGO, and CancerMA to identify cell adhesion-related genes, perform meta-analyses of their expression across various cancers, and then extend these gene lists using co-expression data from cBioPortal.
- Drug Prediction: The L1000CDS2 search engine was used to predict drug classes that could reverse the identified EMT gene signatures.
- Kinase Identification: Expression2Kinases and STRING were used to identify key kinases involved in EMT and construct a kinase-interaction network. Gephi was used for network visualization.
- Drug-Target Mapping: DrugBank was used to map identified kinases to FDA-approved drugs.
- Experimental Validation: A 3D microfluidic co-culture model of cancer cells and endothelial cells was used to experimentally validate the anti-EMT efficacy of the predicted drug combinations, measuring cell dispersion and invasion.
Datasets
- Published EMT Signatures: Data from Byers et al. [21] and Tan et al. [13], along with two meta-analyses [17, 18].
- Gene Expression Databases: CancerMA, MSigDB, Enrichr, cBioPortal, TCGA, NCI-60 cancer cell line panel, CSIOVDB (ovarian cancer), ImmGen (murine hematopoietic cells).
- Drug-Target Information: DrugBank, iLINCS, DRUGSURV.
- Gene Perturbation Signatures: CREEDS database.
Key Insights and Ideas
- HDACs as Key Regulators: Histone deacetylase inhibitors (HDACIs) emerged as a consistent drug class capable of reversing EMT-associated gene expression across multiple cancer types, suggesting a role in modulating epigenetic plasticity.
- SRC and IKBK as Central Kinases: Network analysis pinpointed SRC and IKBK as crucial intracellular kinases that act as hubs in the complex EMT signaling network, making them attractive targets for intervention.
- Mono-therapy Inadequacy: Single-drug treatments, even at low doses, were insufficient to fully inhibit cancer cell dispersion and invasion in the 3D model, underscoring the need for combinatorial approaches.
- Synergistic Triple Combination: A combination of an HDACI (Vorinostat) with SRC (Dasatinib) and IKBK (Aspirin/Sulfasalazine) inhibitors demonstrated a robust inhibition of EMT, including cell dispersion and endothelial cell invasion, in a physiologically relevant 3D model.
Key Results
- A comprehensive EMT gene signature library of 962 genes was generated.
- HDACIs were identified as a notable class of drugs reversing EMT-associated gene expression in ten out of eleven solid cancers analyzed.
- Network analysis revealed SRC as the hub node and IKBK as a principal kinase in the EMT network.
- In the 3D microfluidic model, mono-therapy with Vorinostat (1µM) did not significantly reduce cancer cell dispersion.
- A triple combination of Vorinostat, Dasatinib, and Aspirin (each at 1µM) fully inhibited cancer cell dispersion and invasion, maintaining the integrity of co-cultured endothelial cells.
Limitations and Future Work
- In Silico to In Vivo Gap: While the study successfully translated in silico findings to in vitro validation, the authors acknowledge that further in vivo studies are necessary.
- Clinical Translation: The proposed drug combination is based on FDA-approved drugs, which is a significant step towards clinical translatability, but clinical trials are still required to confirm efficacy and safety in human patients.
- Complexity of EMT: The paper highlights that EMT is a complex, multi-step process, and while their combination targets key players, other pathways might still contribute to resistance or incomplete inhibition. Future work could explore further refining the combination or investigating resistance mechanisms.
Summary updated